We are international
Donate
TEXT SIZE   

The IMF brings you highlights from the 51st annual meeting of the American Society of Clinical Oncology (ASCO) held May 29-June 2, 2015 in Chicago, Illinois. The ASCO Annual Meeting brings together more than 25,000 oncology professionals from a broad range of specialties.

We are currently editing more videos from ASCO and will be uploading once they are done. Stay tuned!

ASCO 2015
    next      view all

Overview
06.11.15   Dr. Kenneth Anderson - ASCO 2015 Highlights

Dr. Ken Anderson
Dana-Farber Cancer Institute
Boston, Massachusetts, USA


06.11.15   Dr. Paul Richardson - ASCO 2015 Highlights

Dr. Paul Richardson
Dana-Farber Cancer Institute
Boston, Massachusetts, USA


06.04.15   Dr. Shaji Kumar overview of ASCO 2015

Dr. Shaji Kumar's overview on what abstracts and posters generated the most excitement for the field of Multiple Myeloma at ASCO 2015.


05.31.15   Dr. Morie A. Gertz ASCO 2015 Overview

Dr. Morie A. Gertz overview on Frontline Therapies presented at ASCO 2015.


06.09.15   Carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed multiple myeloma (RMM): Results from the phase III study ENDEAVOR

Dr. Meletios Dimopoulos
National and Kapodistrian
University of Athens
Athens, Greece


06.09.15   Safety and efficacy of anti-CD19 chimeric antigen receptor (CAR)-modified autologous T cells (CTL019) in advanced multiple myeloma

Dr. Edward A. Stadtmauer
Abramson Cancer Center
Philadelphia, Pennsylvania USA


06.05.15   A randomized phase II study of bortezomib (Btz)/dexamethasone (dex) with or without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

Dr. Adrzej Jakubowiak
University of Chicago Medical Center
Chicago, Illinois, USA


06.05.15   Cardiac and renal biomarker responses in a phase 1/2 study of NEOD001 in patients with AL amyloidosis and persistent organ dysfunction.

Dr. Morie Gertz
Mayo Clinic
Rochester, MN


06.05.15   Phase II MMRC trial of extended treatment with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) plus autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM)

Dr. Andrzej Jakubowiak
University of Chicago Medical Center
Chicago, Illinois,  USA


06.04.15   ELOQUENT-2: A phase III, randomized, open-label study of lenalidomide (Len)/dexamethasone (dex) with/without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

Dr. Sagar Lonial
Emory University
Atlanta, GA, USA


    next      view all